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Abstract 
Background: There is a lack of evidence pointing to the efficacy of any specific 
psychotherapy for adults with anorexia nervosa (AN). The aim of this study was to compare 
three psychological treatments for AN: Specialist Supportive Clinical Management (SSCM), 
Maudsley Model Anorexia Nervosa Treatment for Adults (MANTRA) and Enhanced 
Cognitive Behavioural Therapy (CBT-E).   
Method: A multi-centre randomised controlled trial.  Outcomes were assessed at pre-, mid-, 
and post-treatment and 6- and 12-month follow-up by researchers blind to treatment 
allocation.  All analyses were intention-to-treat.  One hundred and twenty individuals meeting 
diagnostic criteria for AN were recruited from outpatient treatment settings in three 
Australian cities.  Participants attended 25-40 sessions over a 10 month period. Primary 
outcomes were BMI and eating disorder psychopathology. Secondary outcomes were 
measures of depression, anxiety, stress and psychosocial impairment. 
Results: Treatment was completed by 60% of participants and 52.5% completed 12 month 
follow-up. Completion rates did not differ between treatments. There were no significant 
differences between the treatments on continuous outcomes; all resulted in clinically 
significant improvements in BMI, eating disorder psychopathology, general psychopathology 
and psychosocial impairment that were maintained over 12 month follow-up. There were no 
significant differences between the treatments with regard to the achievement of a healthy 
weight (mean = 50%) or remission (mean = 28.3%) at 12 month follow-up.   
Conclusion: The findings add to the evidence base for these three psychological treatments 
for adults with AN but the results underscore the need for continued efforts to improve 
outpatient treatments for this disorder. 
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Anorexia Nervosa (AN) is a serious mental disorder that has a substantial effect on 
psychological, physical, social and vocational functioning (Arcelus et al., 2011; Mitchison et 
al., 2013; Paxton et al., 2012; Steinhausen, 2002; Stice et al., 2013; Treasure et al., 2001). It 
is notoriously difficult to treat and tends to run a chronic course (Steinhausen, 2002; Stice et 
al., 2013).  Progress has been made in treating younger patients using family-based 
approaches (le Grange and Eisler, 2009) but there is little convincing evidence to suggest that 
any psychological or pharmacological treatment consistently produces good outcomes for 
adults with AN.  Nor is there evidence pointing to the superiority of any one treatment above 
another (Hay et al., 2015; National Collaborating Centre for Mental Health, 2004; Watson 
and Bulik, 2013; Zipfel et al., 2015). 
 In the past decade two new psychological treatments have been developed for, and evaluated 
with, AN; the Maudsley Model Anorexia Nervosa Treatment for Adults (MANTRA) 
(Schmidt and Treasure, 2006)
 
and Enhanced Cognitive Behavioural Therapy (CBT-E) 
(Fairburn, 2008). MANTRA targets factors specific to the cognitive-interpersonal theory of 
the maintenance of AN.
  
CBT-E is based on a cognitive behavioural theory of the processes 
maintaining eating disorder psychopathology, and is a trans-diagnostic treatment designed for 
all eating disorders (Fairburn et al., 2003; Fairburn, 2008).  
MANTRA has been the focus of two randomised controlled trials (RCTs) (Schmidt et al., 
2012, 2015) involving 72 and 142 participants respectively, both of which involved a 
comparison with Specialist Supportive Clinical Management (SSCM) (McIntosh et al., 2005, 
2010).  SSCM is derived from the typical supportive approach of specialists to the 
management of AN. Both studies showed sustained improvements in eating disorder features 
and weight and no significant differences between MANTRA and SSCM (McIntosh et al., 
2005; Schmidt et al., 2012; Touyz et al., 2013). In the first of these RCTs (Schmidt et al., 
2012) the mean BMI increase from baseline to 12 months post-randomization (end of 
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treatment) for MANTRA and SSCM respectively was 1.37 kg/m
2 
and 1.22 kg/m
2
. In the later 
multi-centre RCT (the MOSAIC Study; Schmidt et al., 2015), the mean BMI increase at the 
same time point was 1.75 kg/m
2  
for MANTRA and 1.36 kg/m
2 
for SSCM.  These 
improvements in BMI increased to 2.25 kg/m
2 
and 2.16 kg/m
2 
at 24 months post-
randomisation (Schmidt et al., 2016).  
The use of outpatient CBT-E in AN has been the focus of a three-centre cohort study 
involving adults (Fairburn, 2013; N=99) and a further cohort study involving adolescents 
(Dalle Grave et al., 2013; N=46).These studies have reported positive and equivalent findings 
across the treatment centres.  In the Fairburn cohort study, mean BMI increased by 1.8 kg/m
2
 
from baseline to end of treatment (a period of 10 months) and this increase was maintained 
(1.7 kg/m
2
) over a 60 week period of follow-up (i.e., 24 months post-randomisation).  A 
variant of CBT-E has been compared with focal psychodynamic therapy (FPT) and 
"optimized treatment as usual" (TAU) in a multi-centre RCT involving 242 adults (the 
ANTOP Study).  The improvements obtained with the three treatments were modest and 
there were no significant differences among them (mean BMI increase by end of 10 months 
of treatment of 0.73 kg/m
2
 for FPT; 0.93 kg/m
2 
for CBT-E and 0.69 kg/m
2
 for TAU and at 12 
months follow-up [22 months post-randomisation] 1.64 kg/m
2
 for FPT; 1.30 kg/m
2
 for CBT-
E and 1.22 kg/m
2
 for TAU). It therefore appears that, regardless of the type of outpatient 
therapy, a weight gain between 0.69-1.80 kg/m
2 
over a 12-month period can be expected, 
rising to between 1.22 and 2.25 kg/m
2
 at 24 months. CBT-E has not previously been 
compared with MANTRA or SSCM.   
The aim of the current trial was to compare the efficacy of these three psychotherapies for 
AN.  The primary outcomes were BMI and global eating disorder psychopathology, and 
secondary outcomes were measures of depression, anxiety, stress and psychosocial 
impairment.  It was hypothesized that CBT-E and MANTRA would be superior to SSCM in 
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terms of weight gain and eating disorder psychopathology as they both focus on specific 
maintaining processes. 
Method 
Study Overview 
The Strong Without Anorexia Nervosa (SWAN) study was a multi-centre RCT involving five 
treatment centres from three Australian States. Across all three treatments participants were 
offered 25-40 fifty-minute sessions over a 10 month period. The number of sessions allocated 
was titrated according to the participant's initial BMI (< 16 = 40 sessions, 16 ≥ 17.5 = 30 
sessions, 17.5 ≥18.5 = 25 sessions) to allow for the amount of time required to achieve 
weight regain.  Up to four additional sessions with a close other/parent/partner were 
permitted.  Participants were also able to have up to six booster sessions in the 12 months 
post-treatment. Monitoring of physical risk was conducted by participants’ general 
practitioners. If BMI fell below 14 or medical instability emerged, treatment was suspended 
for up to 21 days for inpatient treatment.  If a participant was unable to rejoin the trial after 21 
days, he/she was withdrawn from the study and the last data points were included in the 
intention-to-treat analyses.  Outcomes were assessed at baseline, mid-treatment, end of 
treatment, and at 6 and 12 months post-treatment by researchers blind to treatment allocation.  
Ethical approval was obtained from Human Research Ethics Committees at each site.  
Recruitment  
Participants were recruited directly from the community (in response to media 
advertisements) and from treatment centres in Perth (University of Western Australia; Centre 
for Clinical Interventions); Adelaide (Flinders University Services for Eating Disorders) and 
Sydney (Sydney University; Western Sydney University).  Appropriate self-referrals and 
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consecutive referred outpatients were assessed and offered participation if they met the 
following inclusion criteria: BMI ≥ 14.0 and < 18.5; 17 years or over; meeting diagnostic 
criteria A and B for AN in the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
edition Revised (DSM-IV-TR) (Association, 2000). These criteria correspond to the current 
DSM-5 diagnostic criteria for AN (American Psychiatric Association, 2012). Exclusion 
criteria were: severe physical or mental illness such that outpatient treatment was 
inappropriate, current severe substance dependence, current use of atypical antipsychotics 
because of the weight gain properties of these drugs, not being available to complete the full 
course of treatment, other active psychotherapy focusing on AN.  
Interventions 
Maudsley Model of Anorexia Nervosa Treatment for Adults (MANTRA) is a formulation-
based treatment accompanied by a patient workbook. Treatment is individually tailored to 
match the clinical symptoms, personality traits and the neuropsychological profile of patients 
(Schmidt et al., 2013, 2014). It effects change through targeting four putative maintaining 
factors (the person’s thinking and emotional/relational style, close others’ responses to the 
illness, and beliefs about the utility of AN in the person’s life; Treasure and Schmidt, 2013).   
Enhanced Cognitive Behaviour Therapy (CBT-E) for underweight patients has three phases 
(Fairburn et al., 2008) and is based on the transdiagnostic maintenance model of eating 
disorders (Fairburn et al., 2003).  In the first, the emphasis is on increasing patients’ 
motivation to change. Then patients are helped to regain weight while at the same time tackle 
their eating disorder psychopathology including their extreme concerns about shape and 
weight.  In the final phase the emphasis is on helping them maintain the changes obtained 
while developing strategies for correcting any setbacks. The focused version of CBT-E was 
used
 
unless lack of progress indicated the use of the broad version. 
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Specialist Supportive Clinical Management (SSCM) combines clinical management and 
supportive psychotherapy within sessions emphasising normalization of eating and 
restoration of weight, specialist psychoeducation and focus on other key symptoms, such as 
vomiting or overexercising. The remainder of the sessions focus on content dictated by the 
patient (McIntosh et al., 2005, 2010; Schmidt et al., 2015). 
 
Therapists  
Therapists (N=8) were psychologists with at least 2 years’ experience using specialized 
psychological treatments for eating disorders.  They delivered all three treatments and 
received training in them in a series of 2 day workshops from the treatment developers (VM 
[SSCM]; US, JT [MANTRA] and CGF [CBT-E]).  Therapists received twice-weekly 
supervision provided by the Australian chief investigators (SB, TW, PH).  One supervision 
session was site-specific and the other was treatment specific involving all therapists, using 
teleconferencing facilities.  Treatment developers were consulted when necessary. All 
treatment sessions were audio-recorded and therapist adherence was found to be excellent 
(Andony et al., 2015). The treatments were highly distinguishable and no inter-site 
differences in therapist adherence were observed (Andony et al., 2015). 
Assessment and outcome measures 
Assessment incorporated semi-structured clinical interviews and self-report questionnaires.  
The Mini International Neuropsychiatric Interview (Sheehan et al., 1998) was used to assess 
other current Axis 1 disorders. Outcomes included BMI, eating disorder features, general 
psychopathology, associated functioning, and a range of additional measures to assess the 
goodness of fit of the theories associated with the different therapies.  
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Eating disorder psychopathology was measured using the global subscale of the Eating 
Disorder Examination (EDE; Fairburn and Wilson, 1993)
 
an investigator-based structured 
interview. Other self-reported outcomes included the short form of the Depression, Anxiety 
and Stress Scale (DASS; Lovibond and Lovibond, 1995) and the Clinical Impairment 
Questionnaire (CIA; Fairburn et al., 2009), 
 
a measure of the severity of psychosocial 
impairment due to eating disorder features.  Participants’ ratings of treatment credibility and 
the likely effectiveness of treatment were assessed at mid-treatment using a 4 item Credibility 
and Expectations Questionnaire (CEQ; Borkovec and Nau, 1972; Devilly and Borkovec, 
2000) adapted for this study (Carter et al., 2012). Items were rated using a 9 point Likert scale 
and scores were summed and divided by 4.  Treatment credibility, acceptability and 
perceived effectiveness was also assessed at post-treatment using the CEQ (worded in the 
past tense). 
Randomisation 
The generation and implementation of the randomisation sequence was conducted, 
independently, by the study coordinator (KA).  Participant randomisation followed 
CONSORT guidelines (Boutron et al., 2008)
 
and made use of stratification with blocking, to 
ensure that treatment groups were generated with approximately equal numbers. 
Randomisation was stratified by site and BMI (BMI <17.5; BMI≥17.5). Randomisation codes 
were generated electronically and then placed in sequentially numbered, sealed, opaque 
envelopes, to be opened at the point of randomisation (following initial assessment). 
Data analyses 
Sample size calculations were performed for the primary outcome hypotheses on an 
intention-to-treat basis. Power calculations were based upon determining power for 
longitudinal designs with attrition (Hedeker et al., 1999) with a two-tailed alpha of .05, five 
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assessment points (with baseline serving as a covariate), attrition rates of 40%, and a fixed 
autoregressive coefficient of .40.  An enrolled sample size of 40 per group would provide 
80% power at two-sided p < .05 to detect a clinically significant change in Global EDE (0.45 
points), assuming a standard deviation of Global EDE change scores of one (Hedeker et al., 
1999)
 
and also to detect a difference in mean weight gain of one BMI point which, based on 
previous research, would be clinically important to detect (Agras et al., 2000). 
Statistical analyses were based on the intention-to-treat principle and were carried out by a 
biostatistician blind to treatment allocation (RDC). To account for missing data due to 
attrition or withdrawal from the trial, maximum likelihood imputation was implemented.  
Continuous outcome data were analysed using linear mixed effects modelling, with restricted 
maximum likelihood estimation, adjusted or baseline values of the variable under 
investigation.  Effect sizes were calculated using Cohen’s d.  
Chi-Square analyses were used for dichotomous categorical variables (1) achievement of 
healthy weight (BMI > 18.5); (2) having a Global EDE within 1 SD of Australian community 
norms (i.e., < 1.81; Mond et al., 2006) and (3) remission (BMI > 18.5, Global EDE < 1.8 and 
absence of binge eating/purging behaviours). For baseline data compared at one time point 
Chi-square tests (categorical data) and one way analysis of variance or independent samples 
median tests (continuous data) were used.  
Site differences were examined for all primary and secondary outcomes.   
Results  
There were 557 enquiries regarding participation. One hundred and seventy one individuals 
were assessed for eligibility and 120 participants (97.5% female) were randomised between 
May 2010 and December 2013 (see Figure 1).  Seventy two participants (60%) completed 
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treatment (progressed through all stages of treatment).  Completion rates were 57.5% (23/40) 
for SSCM; 56.1% (23/41) for MANTRA and 66.7% (26/39) for CBT-E, χ2 (2) = 1.09, p = 
.58. Thirty four (28.3%) dropped out (defined as non-mutual premature termination of 
treatment; 13 in SSCM, 10 in MANTRA, 11 in CBT-E, χ2 (2) = 0.66, p =.72).  Reasons for 
discontinuing included not wanting to continue with treatment (N=22), inability to attend 
(N=5), moving elsewhere (N=3), and increased work commitments (N=4).  Fourteen 
participants (11.67%) were withdrawn (13 due to BMI dropping below 14 and being unable 
to recommence after 21 days [3 in SSCM, 8 in MANTRA, 2 in CBT-E]; one due to 
recommencing olanzapine [SSCM], χ2 (2) = 0.42, p =.12).  Eight participants (4 in SSCM, 2 
in MANTRA, 2 in CBT-E) had inpatient admissions of < 21 days during treatment and then 
re-joined the trial. Seventy five percent of drop outs or withdrawals (N=35) occurred during 
the first half of treatment. There were no deaths.  The median number of sessions attended 
was 24.5 (1-40) for SSCM, 25 (0-40) for MANTRA and 25 (0-40) for CBT-E (independent 
samples median test (2) = 0.5, p = .78). Of those participants who completed the end of 
treatment assessment (N=73), 63 (86.3%) completed the12 month follow-up.  There were no 
site differences with regard to treatment completion, χ2 (2) = 0.82, p = .66. 
Participant characteristics Baseline demographic and clinical characteristics are 
presented in Table 1. The mean age of the sample was 26.19 (SD = 9.47), median duration of 
illness was 4 years (IQR = 1-8) and over half (52.5%) of the sample had had at least one 
inpatient admission for AN. Mean pre-treatment BMI was 16.70 (SD = 1.22).  The majority 
(82.5%) were Australian born and single (67.1%).  Approximately half (44.2%) met 
diagnosis for AN-restricting subtype with the remainder being AN binge-purge subtype.  
Over one third met criteria for a depressive (38.3%) or anxiety disorder (35.8%) and 46.67% 
were currently taking psychotropic medication.  There were no significant differences 
between the three treatment conditions on any of these characteristics (ps > .05) except that a 
12 
 
significantly smaller proportion of patients in SSCM (22.5% [9/40]) were currently depressed 
compared to CBT-E (51.3% [20/39]) and MANTRA (41.5% [17/41]), χ2 (2) = 6.75, p < .05. 
Participant expectations and treatment credibility 
All treatments were rated highly on the CEQ at both mid-treatment and post-treatment with 
no significant differences in ratings among the three treatments (mid-treatment, F (2, 69) = 
1.64, p = .20; post-treatment, F (2, 64) = 2.43, p = .10) (See Table 1).   
Primary outcomes 
Figure 2 shows mean estimated BMI at each assessment point for the three treatment arms 
(using imputed values).  BMI increased significantly over time across all treatments, F (3, 
353.36) = 25.31, p < .001 and the treatment by time interaction was not significant, F (6, 
353.36) = 1.66, p = .129. CBT-E produced an estimated mean BMI increase of 2.10 (95% CI 
[1.65-2.79]) from baseline to post-treatment, 2.16 (95% CI [1.71-2.85]) from baseline to six 
month follow-up and 2.35 (95% CI [1.90-3.04]) from baseline to 12 month follow-up.  The 
equivalent figures in SSCM were 1.58 (95% CI [1.14-2.25], 1.71 (95% CI [1.28-2.38] and 
1.90 (95% CI [1.47-2.58]); and in MANTRA 1.37 (95% CI [0.62-1.71]), 1.35 (95% CI [0.59-
1.69]) and 1.50 (95% CI [0.74-1.84]).  At 12 month follow-up effect sizes for the differences 
in mean BMI were d = 0.29 for CBT-E vs MANTRA; d = .21 for CBT-E vs SSCM and d = 
.08 for SSCM vs MANTRA. The site by treatment by time interaction was non-significant, F 
(16, 434.60) = 1.61, p = .07. 
Table 2 presents mean Global EDE score at each assessment point for the treatment arms. 
Global EDE decreased significantly over time across all treatments, F (3, 190.11) = 23.38, p 
< .001, with no significant treatment by time interaction, F (6, 190.11) = .75, p = .61. Once 
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again, the site by treatment by time interaction was non-significant, F (16, 424.72) = 0.87, p 
= .60. 
Remission rates  
The percentage of participants who achieved a BMI > 18.5 at each time point is shown in 
Figure 3. At 12 month follow-up a healthy weight had been achieved by 47.5% (19/40) in 
SSCM; 43.9% (18/41) in MANTRA and 59.0% (23/39) in CBT-E, with no differences 
among the treatments χ2 = 1.97, df = 2, p = .37.  The proportion of participants achieving a 
‘normal’ global EDE score (i.e., < 1.81) at 12 month follow-up did not differ across the 
treatments χ2 = 1.73,  df = 2, p = .42 (SSCM = 25/40 [62.5%]; MANTRA = 21/41 [51.2%]; 
CBT-E = 19/39 [48.7%]), nor did the proportion of participants in remission (BMI > 18.5, 
Global EDE < 1.81 and absence of binge eating/purging behaviours); SSCM (32.5% [13/40]), 
MANTRA (22% [9/41]), CBT-E (30.8% 12/39]), χ2 = 1.28, df  = 4, p = .53 (See Table 2).  
There were no significant site differences in the achievement of a healthy weight (χ2 = 3.65, 
df  = 2, p = .16), normal Global EDE score, χ2=  0.27, df  = 2, p = .87) or remission (χ2 = 0.47, 
df  = 2, p = .66). Of those participants who were in remission at end of treatment (31/120 
[25.8%]), 25 (80.6%) were still in remission at one year follow-up (SSCM = 11/11; 
MANTRA =  7/11; CBT-E = 7/9) and the remaining six were in partial remission.  Another 
six participants (SSCM = 1, MANTRA = 1, CBT-E = 4) who had not achieved full remission 
by end of treatment, continued to improve over time and did so by 12 month follow-up.  Of 
those participants who completed the 12 month follow-up (N = 63), 23 (36.5%) reported 
attending additional treatment for their eating disorder since the end of treatment (SSCM = 6; 
MANTRA = 9; CBT-E = 8).  This treatment most commonly took the form of less than 
monthly appointments with a psychiatrist and/or psychologist (N = 14).  Three participants 
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received inpatient treatment during the follow-up period (SSCM = 1; MANTRA = 1; CBT-E 
= 1).  
Depression, anxiety, stress and clinical impairment 
On the DASS Depression subscale, there was a significant decrease in scores from baseline to 
12 month follow-up across all treatment groups, F (3,250.72) = 10.21, p <  .001. The 
treatment by time interaction was also significant, F (6,250.72) = 2.40, p <.003, due to 
differences in the trajectories of change (See Table 2).  On both the Anxiety and Stress 
subscales of the DASS there was a significant decrease in scores over time in all treatments 
(Anxiety: F (3, 218.13) = 6.37, p < .001; Stress: F (3, 226.70) = 8.66, p < .001); and no 
treatment by time interaction (Anxiety: F (6, 218.13) = .99, p = .43; Stress: F (6, 226.70) = 
0.90, p = .50). CIA scores also decreased significantly over time across all treatments, F (3, 
348.35) = 16.91, p < .001, with no treatment by time interaction, F (6, 348.35) = 1.48, p = 
.18. The site by treatment by time interaction was non-significant for all of these secondary 
outcomes.  Estimated means for the DASS and CIA at each time point are shown in Table 2. 
Conclusion  
We compared three outpatient treatments for adults with established AN, a notoriously 
treatment-resistant disorder. All three treatments were acceptable to patients and all resulted 
in improvements in weight and eating disorder psychopathology that were well maintained 
over a 12 month follow-up, although remission rates were low.  There were no significant 
differences among the treatments with regard to BMI change over time or the achievement of 
a healthy BMI at 12-month follow-up.  There was no difference between the treatments in the 
rate of improvement in eating disorder psychopathology, nor in the proportion of participants 
scoring in the normal range on the global EDE at 12 month follow-up.  All treatments were 
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associated with a significant reduction in general psychopathology and psychosocial 
impairment.   
 
Comparison of outcomes with previous clinical trials 
Direct comparisons of our findings with those from previous trials need to be made with 
caution given the differences between the samples studied; differences in the way that the 
treatments have been implemented; and the different ways the findings have been 
analysed.  Weight regain is one variable that is consistently reported and, as it is a central 
goal of treatment, it can be compared across the studies. For CBT-E, the percentage of 
participants achieving a healthy weight at post-treatment and 12 month follow-up (22 months 
post-randomisation) in the current study (53.8% and 59% respectively) is higher than the 
rates reported in the three-centre UK-Italy study (48%, 44%; Fairburn et al., 2013) and the 
mean BMI gain from baseline to end of treatment (2.1kg/m
2
) is slightly greater (1.8kg/m
2
). 
The mean BMI increase for CBT-E in this study is also greater than that reported for CBT-E 
in the ANTOP study (0.93 kg/m
2
). For SSCM, the mean BMI gain from baseline to end of 
treatment in the current study (1.58kg/m
2
) is similar to that reported in the first SSCM trial 
(1.5kg/m
2
; McIntosh et al., 2005) and in the MOSAIC study (1.36kg/m
2
; Schmidt et al., 
2015).  For MANTRA, however, mean post-treatment and follow-up BMI gains were less in 
the current study (1.37 kg/m
2  
and 1.5 kg/m
2 
respectively) than in the MOSAIC study 
(1.75kg/m
2
 and 2.25 kg/m
2
 respectively) (Schmidt et al., 2015).  Thus, in the current trial, in 
regard to weight regain, CBT-E performed better than in previous studies, SSCM performed 
similarly and MANTRA performed less well. 
Strengths and Limitations 
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The study had several strengths, a major one being that the treatments were delivered in ‘real 
world’ outpatient settings by therapists with varying degrees of experience.  The assessments 
were conducted by assessors blind to treatment condition, statistical analyses were conducted 
by an independent biostatistician and attention was paid to measuring and ensuring therapist 
adherence (Andony et al., 2015). 
The study also had limitations. The non-completion rate was high, although not unusually so 
for clinical trials in the field of eating disorders.  The distribution of participants across sites 
was uneven, with more recruited to the Perth site than to Adelaide or Sydney.  In addition, 
although therapist adherence to treatment protocols was measured, therapist competence was 
not assessed (Fairburn and Cooper, 2011) which may have been valuable given the fact that 
the majority of the therapists involved in this RCT had been primarily trained in cognitive 
behaviour therapy. 
Final Comments 
The findings of this study add to the evidence base for these three outpatient psychological 
treatments in the management of adults with AN.  The treatments did not differ in their 
effectiveness.  While significant improvements in weight and eating disorder symptoms were 
observed in all treatments, only half of the participants were in the healthy weight range at 
the 12 month follow-up and less than one third were in remission.  The results of this study 
highlight just how difficult it is to achieve good outcomes with currently available treatments 
for adults with AN and underscore the need for continued efforts to improve outpatient 
treatments for this disorder. 
.   
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Figure 3 
Percentage of participants achieving a healthy weight (BMI > 18.5) at each time point 
(using the full data set with imputed values). 
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Table 1: Baseline characteristics of the sample  
Demographics Entire sample 
N =120 
SSCM 
N=40 
MANTRA 
N=41 
CBT-E 
N=39 
Age, years (mean [SD]) 26.19 (9.47) 28.44 (10.94) 25.95 (9.00) 24.18 (8.00) 
Males: Females (n) 5:115 3:37 1:40 1:38 
Country of birth     
Australia 
U.K. 
South Africa 
Other 
 
99 (82.50) 
9 (7.50) 
5 (4.17) 
7 (5.83) 
 
33 (82.50) 
2 (5.00) 
1 (2.50) 
4 (7.50) 
 
33 (80.49) 
4 (9.75) 
2 (4.88) 
2 (4.88) 
 
33(84.61) 
3 (7.69) 
2 (5.13) 
1 (2.56) 
Qualifications (n [%])   
High School  
Trade/Technical  
Tertiary 
 
48 (40.00) 
17 (14.17) 
55 (45.83) 
 
16 (40.00) 
2 (5.00) 
22 (55.00) 
 
19 (46.34) 
6 (14.63) 
16 (39.02) 
 
14 (35.90) 
8 (20.51) 
17 (43.59) 
Relationship status (n [%])   
Single (never married) 
Married/de facto 
Sep/Divorced/Widowed 
 
80 (66.67) 
36 (30.00) 
4 (3.33) 
 
26 (65.00) 
14 (35.00) 
0 (0) 
 
25 (60.98) 
14 (34.15) 
2 (4.8) 
 
29 (74.36) 
8 (20.51) 
2 (5.13) 
Clinical characteristics 
AN-Restricting subtype 
AN-Binge/purge subtype 
53 (44.17) 
67 (55.8) 
21 (52.5) 
19 (47.5) 
20 (48.78) 
21 (51.2) 
12 (30.77) 
27 (69.2) 
BMI, kg/m2 (mean [SD]) 16.70 (1.22) 16.58 (1.18) 16.91 (1.11) 16.59 (1.35) 
BMI range (n[%]) 
14> 16 
16 ≥ 17.5 
17.5 ≥ 18.5 
 
32 (26.7) 
50 (41.7) 
38 (31.7) 
 
8 (20) 
17 (42.5) 
15 (37.5) 
 
12 (29.3) 
18 (43.9) 
11 (26.8) 
 
12 (30.8) 
15 (38.5) 
12 (30.8) 
2 
 
Duration of illness, years (median [IQR])a 4 (1-8) 2 (1-8) 5 (1-9) 4 (1-7.5) 
Previous inpatient eating disorder 
treatment (n [%]) 
63 (52.5) 22 (55.00) 19 (46.34) 22 (56.41) 
Global EDE (mean [SD]) 3.32 (1.40) 3.07 (1.30) 3.38 (1.49) 3.52 (1.40) 
Current major depression (n [%])b 46 (38.33) 9 (22.50) 17 (41.46) 20 (51.28) 
Current suicidal ideation 49 (40.83) 11 (27.50) 17 (41.46) 21 (53.85) 
Current Anxiety Disorder (n [%]) 
GAD 
Social Phobia 
OCD 
Panic disorder 
 
43 (35.8) 
29 24.17) 
22 (18.33) 
18 (15.00) 
 
14 (35.9) 
7 (17.50) 
5 (12.50) 
4 (10.00) 
 
15 (36.6) 
8 (19.51) 
7 (17.07) 
7 (17.07) 
 
14 (35.9) 
14 (35.90) 
10 (25.64) 
7 (17.95) 
Alcohol Dependence 11 (9.17) 1 (2.50) 4 (9.76) 6 (18) 
Substance abuse 5 (4.17) 2 (5.00) 2 (4.88) 1 (2.56) 
Current psychiatric medication (n [%]) 56 (46.67) 19 (48.70) 21 (51.22) 16 (41.02) 
Treatment credibility and participant 
expectations 
Mid-treatment CEQ (mean [SD]) 
Post-treatment CEQ (mean ]SD]) 
 
 
6.64 (1.76) 
6.84 (1.76) 
 
 
7.22 (1.66) 
7.58 (1.44) 
 
 
6.27 (1.95) 
6.41 (2.00) 
 
 
6.53 (1.59) 
6.69 (1.64) 
Note: all ps > .05; BMI = Body Mass Index; IQR= Interquartile Range; EDE = Eating 
Disorder Examination; GAD = Generalized Anxiety Disorder; OCD = Obsessive Compulsive 
Disorder; CEQ = Credibility/Expectations Questionnaire; 
a
Independent Samples Median Test 
(2)=2.99, p=.22
;  bꭔ2 = 6.75 df =2, p <.05  
3 
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Table 2 
Estimated mean Global EDE, DASS and CIA scores at each time point for the three treatment arms (using full data set with imputed values).   
 
 Total Sample SSCM MANTRA CBT-E 
 Pre          Mid EOT 6 mth 12 mth Pre Mid EOT 6 mth 12 mth Pre Mid EOT 6 mth 12mth Pre Mid EOT 6 mth 12 mth 
Global EDE  
Mean 
(SD) 
 
Normal Global 
EDE score (< 
1.81) n (%) 
 
 
3.32 
(1.40) 
 
22 
(18.3) 
 
 
2.43 
(1.13) 
 
39 
(32.5) 
 
 
1.93 
(1.13) 
 
51 
(42.5) 
 
 
1.94 
(1.12) 
 
49 
(40.8) 
 
 
1.77 
(1.13) 
 
55 
(45.8) 
 
 
3.32 
(1.40) 
 
8 
(20) 
 
 
2.28 
(1.10) 
 
15  
(37.5) 
 
 
1.79 
(1.16) 
 
19 
(47.5) 
 
 
1.92 
(1.17) 
 
17  
(42.5) 
 
 
1.59 
(1.10) 
 
22 
(55.0) 
 
 
3.32 
(1.40) 
 
8 
(19.5) 
 
 
 
2.32 
(1.24) 
 
16 
(39.0) 
 
 
1.87 
(1.19) 
 
18 
(43.9) 
 
 
1.85 
(1.07) 
 
17 
(41.5) 
 
 
1.78 
(1.19) 
 
18 
(43.9) 
 
 
3.32 
(1.40) 
 
6 
(15.4) 
 
 
2.70 
(1.13) 
 
8 
(11.6) 
 
 
2.13 
(1.09) 
 
14 
(35.9) 
 
 
2.06 
(1.14) 
 
15 
(38.5) 
 
 
1.93 
(1.16) 
 
15 
(38.5) 
DASS- Dep  
Mean 
(SD) 
 
9.65 
(6.57) 
 
7.17 
(4.87) 
 
6.81 
(4.80) 
 
7.75 
(4.73) 
 
5.81 
(4.82) 
 
9.65 
(6.57) 
 
7.28 
(5.01) 
 
5.91 
(5.04) 
 
8.40(5.01
) 
 
6.00 
(5.00) 
 
9.65 
(6.57) 
 
6.22 
(4.79) 
 
6.90 
(4.69) 
 
7.43 
(4.56) 
 
5.69 
(4.71) 
 
9.65 
(6.57) 
 
8.01 
(4.78) 
 
7.62 
(4.67) 
 
7.42 
(4.79) 
 
5.73 
(4.72) 
DASS-Anxiety 
Mean 
(SD) 
 
5.85 
(4.73) 
 
4.05 
(3.77) 
 
4.25 
(3.88) 
 
3.50 
(3.62) 
 
3.31  
(3.02) 
 
5.85 
(4.73) 
 
4.05 
(3.81) 
 
3.96 
(3.73) 
 
3.72 
(3.94) 
 
3.48 
(3.78) 
 
5.85 
(4.73) 
 
3.45 
(3.26) 
 
3.90 
(3.21) 
 
3.04 
(2.72) 
 
3.12 
(3.15) 
 
5.85 
(4.73) 
 
4.63(3.
80) 
 
4.88 
(3.14) 
 
3.73 
(3.39) 
 
3.33 
(3.31) 
DASS-Stress 
Mean 
(SD) 
 
11.58 
(5.15) 
 
9.02 
(4.77) 
 
7.85 
(4.66) 
 
7.76 
(4.53) 
 
7.54  
(4.73) 
 
11.58 
(5.15) 
 
8.95 
(4.76) 
 
7.52 
(4.72) 
 
7.89(4.75
) 
 
7.62  
(4.80) 
 
11.58 
(5.15) 
 
8.45 
(4.69) 
 
7.98 
(4.54) 
 
7.49 
(4.30) 
 
7.56 
(4.51) 
 
11.58 
(5.15) 
 
9.66 
(4.87) 
 
8.04 
(4.78) 
 
7.88 
(4.58) 
 
7.43 
(4.85) 
CIA 
Mean 
(SD) 
 
32.82 
(10.76) 
 
25.03 
(13.89) 
 
21.34 
(13.53) 
 
20.04 
(12.99) 
 
20.81 
(14.17) 
 
32.82 
(10.76) 
 
24.47 
(13.89) 
 
20.72 
(13.98) 
 
20.30 
(14.06) 
 
19.19 
(14.41) 
 
32.82 
(10.76) 
 
23.76 
(14.29) 
 
20.94 
(13.48) 
 
18.83 
(12.22) 
 
21.22 
(15.70) 
 
32.82 
(10.76) 
 
26.87 
(13.66) 
 
22.36 
(13.44) 
 
20.99 
(12.95) 
 
22.01 
(13.52) 
Note:  EDE = Eating Disorder Examination; DASS = Depression, Anxiety and Stress Scale; CIA = Clinical Impairment Questionnaire; Pre = pre-treatment 
(baseline); Mid = mid-treatment; EOT= end of treatment; 6 mth = six months post-treatment; 12 mth = 12 months post-treatment 
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